R., M., P., P. H., & R., M. H. (2016). A prospective analysis of the cost-effectiveness of alfuzosin, tamsulosin and silodosin for 12 weeks in benign prostatic hyperplasia. International Journal of Basic & Clinical Pharmacology, 5(6), 2481–2487. https://doi.org/10.18203/2319-2003.ijbcp20164109